Yue’s study demonstrated that PKP can improve lipid metabolism disorders by activating peroxisome proliferator-activated receptor gamma (PPARγ) in adipocytes and inhibiting the Toll-like receptor 4/nuclear factor kappa B (TLR4/NFκB) signaling pathway. Here, NFKB1 is linked to Disorder of lipid metabolism.